Observational studyUnited European gastroenterology journal2025
Tackling Post-Endoscopy Gastric Cancer in a Low-Risk Area: Prevalence, Features, and Prevention Opportunities Through Better Clinical Practice.
Observational study in United European gastroenterology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tackling Post-Endoscopy Gastric Cancer in a Low-Risk Area: Prevalence, Features, and Prevention Opportunities Through Better Clinical Practice.United European gastroenterology journal · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
Abstract
backgroundPost-endoscopy gastric cancer (PEGC) is a gastric cancer (GC) diagnosed within 3 years after an esophago-gastro-duodenoscopy (EGD) negative for cancer. Post-endoscopy gastric cancer has a prevalence of 9%-11% in the western population and is potentially reducible through adequate surveillance and high-quality endoscopy. However, Post-Endoscopy Gastric Cancer features are not well defined.
objectivesDefine Post-Endoscopy Gastric Cancer prevalence in a gastric cancer low-risk area as Spain, describe its characteristics and associated factors. Evaluate adherence to current recommendations for surveillance of preneoplastic gastric lesions and endoscopic quality indicators.
methodsA descriptive and analytical study included patients who met PEGC criteria and enrolled in the EpiGASTRIC registry-a national multicentric GC cohort-between April 2021 and May 2024.
resultsOf 289 gastric cancer patients analyzed, 21 (7.3%) presented with PEGC. No differences were found between PEGCs and new-onset gastric cancers (NOGC) regarding clinical-demographic characteristics (males 52.4%, 65 years, caucasians 78.9%, previous Helicobacter pylori infection 56.3%) except for use of proton pump inhibitors (PPI) (81.0% vs. 44.9%, p-value = 0.002). Distal stomach (antrum and/or incisure) was more frequently affected in PEGC compared with NOGC (71.4% vs. 46.2%; p-value = 0.022), without differences in tumoral staging (I-II 52.4%) or histology (intestinal type 47.6%). Median time from last negative-for-cancer EGD to diagnosis was 13.6 months (interquartile range 4.1-26.8), with 38.1% of precursor lesions in previous endoscopy (19% chronic atrophic gastritis with metaplasia, 19% dysplasia). Considering last negative-for-cancer EGD, adherence to current recommendations was 66.6% for the surveillance of gastric lesions, and 14.3% for quality indicators (complete procedure 100%, high-definition 38.1%, chromoendoscopy 10.0%).
conclusionsPEGC patients present a higher rate of distal stomach involvement and use of PPIs. Although precursor gastric lesions are commonly identified, adherence to current recommendations for their surveillance and to established quality indicators in EGDs is scarce. Despite its low prevalence, there is room for improvement to enhance the early detection and prevention strategies for PEGC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.